1-3 of 3
Neal Shore
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide

Wassim Abida, Andrew W. Hahn, Neal Shore, Neeraj Agarwal, Paul Sieber, Matthew R. Smith, Tanya Dorff, Paul Monk, Matthew Rettig, Rupal Patel, Anne Page, Maureen Duff, Rongda Xu, Jian Wang, Shravani Barkund, Aleksandr Pankov, Amber Wang, Melissa R. Junttila, Pratik S. Multani, Anneleen Daemen, Edna Chow Maneval, Christopher J. Logothetis, Michael J. Morris
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (6): 1111–1120.
https://doi.org/10.1158/1078-0432.CCR-23-3508
Published: 15 March 2024
View article titled, Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
Open the PDF for Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide in another window
Includes: Supplementary data
Journal Articles

Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Maha Hussain, Claire Corcoran, Caroline Sibilla, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Joaquin Mateo, David Olmos, Niven Mehra, Michael P. Kolinsky, Guilhem Roubaud, Mustafa Özgüroǧlu, Nobuaki Matsubara, Craig Gedye, Young Deuk Choi, Charles Padua, Alexander Kohlmann, Robert Huisden, Julia A. Elvin, Jinyu Kang, Carrie A. Adelman, Allison Allen, Christian Poehlein, Johann de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1518–1530.
https://doi.org/10.1158/1078-0432.CCR-21-3940
Published: 14 April 2022
View article titled, Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Open the PDF for Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib) in another window
Includes: Supplementary data
Journal Articles

Abstract PO-077: Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH) - Trial in progress

Kim N. Chi, Ur Metser, Johannes Czernin, Jeremie Calais, Vikas Prasad, Matthias Eiber, Neal Shore, Jessica Jensen, Neil Fleshner, Scott Tagawa, Oliver Sartor
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8_Supplement): PO-077.
https://doi.org/10.1158/1557-3265.RADSCI21-PO-077
Published: 15 April 2021
View article titled, Abstract PO-077: Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using <sup>177</sup>Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH) - Trial in progress